厄他培南治疗产超广谱β-内酰胺酶肠杆菌科血流感染的疗效。
Efficacy of ertapenem for treatment of bloodstream infections caused by extended-spectrum-β-lactamase-producing Enterobacteriaceae.
机构信息
Division of Infectious Diseases, Wayne State University, Detroit, Michigan, USA.
出版信息
Antimicrob Agents Chemother. 2012 Apr;56(4):2173-7. doi: 10.1128/AAC.05913-11. Epub 2012 Jan 30.
Abstract
Ertapenem is active against extended-spectrum-β-lactamase (ESBL)-producing Enterobacteriaceae organisms but inactive against Pseudomonas aeruginosa and Acinetobacter baumannii. Due to a lack of therapeutic data for ertapenem in the treatment of ESBL bloodstream infections (BSIs), group 2 carbapenems (e.g., imipenem or meropenem) are often preferred for treatment of ESBL-producing Enterobacteriaceae, although their antipseudomonal activity is unnecessary. From 2005 to 2010, 261 patients with ESBL BSIs were analyzed. Outcomes were equivalent between patients treated with ertapenem and those treated with group 2 carbapenems (mortality rates of 6% and 18%, respectively; P = 0.18).
摘要
厄他培南对产超广谱β-内酰胺酶（ESBL）的肠杆菌科细菌具有活性，但对铜绿假单胞菌和鲍曼不动杆菌无活性。由于缺乏厄他培南治疗产 ESBL 血流感染（BSI）的治疗数据，因此常选择第 2 代碳青霉烯类药物（如亚胺培南或美罗培南）治疗产 ESBL 的肠杆菌科细菌，尽管它们的抗假单胞菌活性是不必要的。2005 年至 2010 年，分析了 261 例产 ESBL BSI 患者。接受厄他培南和第 2 代碳青霉烯类药物治疗的患者的结局相当（死亡率分别为 6%和 18%；P=0.18）。
相似文献
1
Efficacy of ertapenem for treatment of bloodstream infections caused by extended-spectrum-β-lactamase-producing Enterobacteriaceae.厄他培南治疗产超广谱β-内酰胺酶肠杆菌科血流感染的疗效。
Antimicrob Agents Chemother. 2012 Apr;56(4):2173-7. doi: 10.1128/AAC.05913-11. Epub 2012 Jan 30.
2
Carbapenem MICs in Escherichia coli and Klebsiella Species Producing Extended-Spectrum β-Lactamases in Critical Care Patients from 2001 to 2009.2001年至2009年重症监护患者中产超广谱β-内酰胺酶的大肠埃希菌和克雷伯菌属的碳青霉烯最低抑菌浓度
Antimicrob Agents Chemother. 2017 Mar 24;61(4). doi: 10.1128/AAC.01718-16. Print 2017 Apr.
3
4
Carbapenem therapy for bacteremia due to extended-spectrum-β-lactamase-producing Escherichia coli or Klebsiella pneumoniae: implications of ertapenem susceptibility.产超广谱β-内酰胺酶大肠埃希菌或肺炎克雷伯菌菌血症的碳青霉烯类治疗：厄他培南药敏的意义。
Antimicrob Agents Chemother. 2012 Jun;56(6):2888-93. doi: 10.1128/AAC.06301-11. Epub 2012 Mar 19.
5
6
Ertapenem for treatment of extended-spectrum beta-lactamase-producing and multidrug-resistant gram-negative bacteraemia.厄他培南用于治疗产超广谱β-内酰胺酶和多重耐药革兰阴性菌血症。
Ann Acad Med Singap. 2008 Oct;37(10):831-4.
7
Ertapenem for the treatment of bloodstream infections due to ESBL-producing Enterobacteriaceae: a multinational pre-registered cohort study.厄他培南治疗产超广谱β-内酰胺酶肠杆菌科细菌所致血流感染：一项多国预注册队列研究。
J Antimicrob Chemother. 2016 Jun;71(6):1672-80. doi: 10.1093/jac/dkv502. Epub 2016 Feb 22.
8
Antimicrobial susceptibility of clinical Enterobacteriaceae isolates at the emergency department in a regional hospital: A threat of extended spectrum beta-lactamase-producers among nursing home residents.某地区医院急诊科临床分离肠杆菌科细菌的药敏情况：养老院居民中广谱β-内酰胺酶产生菌的威胁
J Microbiol Immunol Infect. 2016 Aug;49(4):584-90. doi: 10.1016/j.jmii.2015.10.001. Epub 2015 Nov 19.
9
Efficacy and safety of de-escalation therapy to ertapenem for treatment of infections caused by extended-spectrum-β-lactamase-producing Enterobacteriaceae: an open-label randomized controlled trial.降阶梯治疗至厄他培南用于治疗产超广谱β-内酰胺酶肠杆菌科细菌所致感染的疗效与安全性：一项开放标签随机对照试验
BMC Infect Dis. 2017 Mar 1;17(1):183. doi: 10.1186/s12879-017-2284-1.
10
Clinical outcomes with ertapenem as a first-line treatment option of infections caused by extended-spectrum β-lactamase producing gram-negative bacteria.厄他培南作为产超广谱β-内酰胺酶革兰氏阴性菌感染一线治疗选择的临床结果。
Ann Pharmacother. 2012 Mar;46(3):347-52. doi: 10.1345/aph.1Q473. Epub 2012 Mar 6.
引用本文的文献
1
Characterizing Ertapenem Neurotoxicity: A Systematic Review and Experience at a Tertiary Medical Center.厄他培南神经毒性的特征：一项系统综述及在三级医疗中心的经验
Open Forum Infect Dis. 2024 Apr 16;11(5):ofae214. doi: 10.1093/ofid/ofae214. eCollection 2024 May.
2
Thirty-Day Mortality Rates in Patients with Extended-Spectrum β-Lactamase-Producing Bacteremia Receiving Ertapenem versus Other Carbapenems.产超广谱β-内酰胺酶菌血症患者接受厄他培南与其他碳青霉烯类药物治疗的 30 天死亡率。
Antimicrob Agents Chemother. 2022 Jul 19;66(7):e0028722. doi: 10.1128/aac.00287-22. Epub 2022 Jun 16.
3
Overcoming Multidrug Resistance of Antibiotics via Nanodelivery Systems.通过纳米递送系统克服抗生素的多重耐药性
Pharmaceutics. 2022 Mar 8;14(3):586. doi: 10.3390/pharmaceutics14030586.
4
Probable ertapenem-induced encephalopathy; case report and suggested alternatives for chronic prostatitis.可能由厄他培南引起的脑病；病例报告及慢性前列腺炎的替代治疗建议。
Daru. 2022 Jun;30(1):159-163. doi: 10.1007/s40199-021-00425-5. Epub 2022 Jan 13.
5
Propensity Score and Desirability of Outcome Ranking Analysis of Ertapenem for Treatment of Nonsevere Bacteremic Urinary Tract Infections Due to Extended-Spectrum-Beta-Lactamase-Producing in Kidney Transplant Recipients.基于倾向性评分和结局排序分析的厄他培南治疗肾移植受者产超广谱β-内酰胺酶大肠埃希菌所致非重症菌血症性尿路感染的效果
Antimicrob Agents Chemother. 2021 Oct 18;65(11):e0110221. doi: 10.1128/AAC.01102-21. Epub 2021 Aug 9.
6
An Evidence-Based Multidisciplinary Approach Focused at Creating Algorithms for Targeted Therapy of BSIs, cUTIs, and cIAIs Caused by in Critically Ill Adult Patients.一种基于证据的多学科方法，专注于为重症成年患者中由[病原体名称未给出]引起的血流感染、复杂性尿路感染和复杂性腹腔内感染创建靶向治疗算法。
Infect Drug Resist. 2021 Jun 30;14:2461-2498. doi: 10.2147/IDR.S314241. eCollection 2021.
7
Emergence of Resistance in to Piperacillin-Tazobactam and Ceftriaxone.对哌拉西林-他唑巴坦和头孢曲松的耐药性出现。
Antimicrob Agents Chemother. 2021 Jan 20;65(2). doi: 10.1128/AAC.01038-20.
8
Choice of therapeutic interventions and outcomes for the treatment of infections caused by multidrug-resistant gram-negative pathogens: a systematic review.治疗多重耐药革兰氏阴性病原体感染的治疗干预措施和结果的选择：系统评价。
Antimicrob Resist Infect Control. 2019 Nov 4;8:170. doi: 10.1186/s13756-019-0624-1. eCollection 2019.
9
Antibiotics and Cure Rates in Childhood Febrile Urinary Tract Infections in Clinical Trials: A Systematic Review and Meta-analysis.抗生素在临床试验中对儿童发热性尿路感染的疗效：系统评价和荟萃分析。
Drugs. 2018 Oct;78(15):1593-1604. doi: 10.1007/s40265-018-0988-1.
10
Treatment of Infections Caused by Extended-Spectrum-Beta-Lactamase-, AmpC-, and Carbapenemase-Producing Enterobacteriaceae.产超广谱β-内酰胺酶、AmpC 酶和碳青霉烯酶肠杆菌科细菌感染的治疗。
Clin Microbiol Rev. 2018 Feb 14;31(2). doi: 10.1128/CMR.00079-17. Print 2018 Apr.
本文引用的文献
1
Fighting bacterial resistance at the root: need for adapted EMEA guidelines.从根源上对抗细菌耐药性：需要适用的欧洲药品管理局指南。
Lancet Infect Dis. 2011 Jan;11(1):6-8. doi: 10.1016/S1473-3099(10)70227-9.
2
Ertapenem-resistant Enterobacteriaceae: risk factors for acquisition and outcomes.产厄他培南耐药肠杆菌科细菌：获得及结局的危险因素。
Infect Control Hosp Epidemiol. 2010 Dec;31(12):1242-9. doi: 10.1086/657138. Epub 2010 Oct 28.
3
Hospital-acquired infections due to gram-negative bacteria.革兰氏阴性菌引起的医院获得性感染。
N Engl J Med. 2010 May 13;362(19):1804-13. doi: 10.1056/NEJMra0904124.
4
Ertapenem administered as outpatient parenteral antibiotic therapy for urinary tract infections caused by extended-spectrum-beta-lactamase-producing Gram-negative organisms.厄他培南作为门诊患者的肠外抗生素治疗，用于治疗产超广谱β-内酰胺酶的革兰氏阴性菌引起的尿路感染。
J Antimicrob Chemother. 2010 Jul;65(7):1510-3. doi: 10.1093/jac/dkq152. Epub 2010 May 11.
5
Ertapenem resistance among extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae isolates.产超广谱β-内酰胺酶肺炎克雷伯菌分离株中的厄他培南耐药性
J Clin Microbiol. 2009 Apr;47(4):969-74. doi: 10.1128/JCM.00651-08. Epub 2009 Feb 11.
6
Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America.有害病菌，无药可医：谨防“ESKAPE”！美国传染病学会的最新报告
Clin Infect Dis. 2009 Jan 1;48(1):1-12. doi: 10.1086/595011.
7
CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting.疾病控制与预防中心/国家医疗安全网络（CDC/NHSN）对医疗保健相关感染的监测定义以及急性护理环境中特定类型感染的标准。
Am J Infect Control. 2008 Jun;36(5):309-32. doi: 10.1016/j.ajic.2008.03.002.
8
Extended-spectrum beta-lactamase-producing Enterobacteriaceae: an emerging public-health concern.产超广谱β-内酰胺酶肠杆菌科细菌：一个新出现的公共卫生问题。
Lancet Infect Dis. 2008 Mar;8(3):159-66. doi: 10.1016/S1473-3099(08)70041-0.
9
Efficacy of ertapenem for consolidation therapy of extended-spectrum beta-lactamase-producing gram-negative infections: a case series report.厄他培南用于产超广谱β-内酰胺酶革兰阴性菌感染巩固治疗的疗效：病例系列报告
Ann Pharmacother. 2008 Feb;42(2):207-12. doi: 10.1345/aph.1K365. Epub 2008 Jan 29.
10
Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008.拯救脓毒症运动：严重脓毒症和脓毒性休克治疗国际指南：2008年版
Crit Care Med. 2008 Jan;36(1):296-327. doi: 10.1097/01.CCM.0000298158.12101.41.
Zotero 插件